AU · rank #6 · 2026-09-07
ABVX
PARIS · EUR · $9.89B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.926 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.33 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $138.97 | +42.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +6.86% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +100.0% |
| 52w high | $139.00 |
| Market cap (USD) | $9.89B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Abivax SA is a clinical-stage biotechnology company focused on developing its lead oral drug candidate, obefazimod, for the treatment of moderately to severely active inflammatory bowel diseases.
Rationale
The quant signal's 42.4% analyst upside and 100% positive revision agreement are supported by a strong clinical momentum profile, an EPS surprise beat, and a recent $800 million capital raise that secures the company's cash runway.
Material risks
- 1Severe binary regulatory risk as Abivax is highly dependent on the FDA NDA submission and subsequent approval of its single lead asset, obefazimod, in late 2026.
- 2Intense market competition in the ulcerative colitis therapeutic class from well-entrenched biologics and other novel oral small molecules.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.